# Nuclide record pluvicto-plus-olaparib (pairing). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/pairings/pluvicto-plus-olaparib/>
  a schema:MedicalTherapy ;
  nuclide:kind "pairing" ;
  schema:identifier "pluvicto-plus-olaparib" ;
  schema:name "177Lu-PSMA-617 (Pluvicto) with olaparib"@en ;
  schema:description "An early trial gave the prostate cancer radiotherapy Pluvicto together with the tablet olaparib, on the idea that the pill makes the radiation harder for the cancer cell to repair. Most men's PSA fell, but this is still a small early-stage study, not proof it helps people live longer."@en ;
  schema:url <https://nuclide.cc/pairings/pluvicto-plus-olaparib/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5005>, <https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-prostate-cancer/144916-asco-2023-luparp-phase-1-trial-of-177lu-psma-617-and-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html>, <https://clinicaltrials.gov/study/NCT03874884> ;
  nuclide:tag "prostate cancer", "PARP inhibitor", "early phase" ;
  nuclide:related <https://nuclide.cc/indications/prostate-mcrpc/>, <https://nuclide.cc/targets/parp/>, <https://nuclide.cc/technologies/radionuclide-parp-combination/>, <https://nuclide.cc/people/sandhu-shahneen/>, <https://nuclide.cc/people/louise-emmett/>, <https://nuclide.cc/isotopes/lu-177/>, <https://nuclide.cc/isotopes/ac-225/> ;
  nuclide:pairs <https://nuclide.cc/drugs/pluvicto/>, <https://nuclide.cc/drugs/olaparib/> .